Abstracts tagged "Outcome measures"

Abstract Number: 2961 • 2015 ACR/ARHP Annual Meeting
Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Veronica J. Berrocal², Gandikota Girish³, Meng Zhang⁴, Chris Hatzis¹, Shervin Assassi⁵, Elana J. Bernstein⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique E. Hinchcliff⁹, Elena Schiopu¹⁰, Virginia D. Steen¹¹, Tracy M. Frech¹² and Dinesh Khanna¹³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Radiology, University of Michigan, Ann Arbor, MI, ⁴Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Georgetown University Medical Center, Washington, DC, ¹²Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Arthropathy and tendinopathy in Systemic Sclerosis (SSc) contribute to disability and are associated with disease progression. Clinical trials in SSc sometimes include the tender…
Abstract Number: 1227 • 2015 ACR/ARHP Annual Meeting
Discrepancies Between Registered and Published Primary Outcomes in Randomized Controlled Trials of Rheumatoid Arthritis
Sheila Lezcano¹, Saha Sajib², Ashley Fan³, Mohini Pathria³, Karina Marianne D. Torralba⁴ and Nasim A. Khan⁵, ¹Internal Medicine, Loma Linda University, Loma Linda, CA, ²Internal Medicine, University of California-Riverside, Riverside, CA, ³Loma Linda University, Loma Linda, CA, ⁴Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ⁵Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Selective outcome reporting may bias treatment effect estimates of clinical trials. Registration of clinical trials was established to improve transparency in their conduct and…
Abstract Number: 3208 • 2015 ACR/ARHP Annual Meeting
Spinal Radiographic Progression in Early Axial Spondyloarthritis: Data from the DESIR Cohort
Sofia Ramiro¹, Désirée van der Heijde¹, Rosaline van den Berg², Victoria Navarro-Compán³, Antoine Feydy⁴, Maria-Antonietta d'Agostino⁵, Damien Loeuille⁶, Maxime Dougados⁷, Monique Reijnierse⁸ and Pascal Claudepierre⁹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, University Hospital La Paz, Madrid, Spain, ⁴Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France, ⁵Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁶Rheumatology, Nancy University Hospital, Nancy, France, ⁷Rheumatology Department, Cochin hospital, Paris-Descartes University, Paris, France, ⁸Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁹Rheumatology, Université Paris Est Créteil, Créteil, France
Background/Purpose: The development of radiographic damage over time has been investigated in patients with AS, but not yet in early axial spondyloarthritis (axSpA). We have…
Abstract Number: 1284 • 2014 ACR/ARHP Annual Meeting
Sensitivity to Change of Patient Preference Outcome Measures for Pain in Trials of Patients with Knee Osteoarthritis
Matthew J. Parkes¹, Michael J. Callaghan¹, Terence W. O'Neill¹ and David T. Felson^1,2, ¹Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose A variety of pain and function instruments are often measured in osteoarthritis (OA) clinical trials. Instruments with maximal sensitivity to change are preferred as the…
Abstract Number: 821 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Christina D Chambers^1,2, Diana L Johnson¹, Yunjun Luo¹, Ronghui Xu^2,3 and Kenneth L Jones¹, ¹University of California San Diego Department of Pediatrics, La Jolla, CA, ²University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, ³University of California San Diego Department of Mathematics, La Jolla, CA
Background/Purpose Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA). Methods The…
Abstract Number: 572 • 2014 ACR/ARHP Annual Meeting
Objective Evaluation of Physical Functioning after TNFi Therapy in Ankylosing Spondylitis Patients; A Selection of Three Feasible Performance-Based Tests
Salima F.E. van Weely¹, Joost Dekker^1,2, Martijn P.M. Steultjens³, Christiaan J. Van Denderen¹, Mike T. Nurmohamed¹, Ben A.C. Dijkmans⁴ and Irene E. van der Horst-Bruinsma⁴, ¹Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, ²Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ³Institute for Applied Health Research and School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, ⁴Rheumatology, VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Physical functioning is considered an important outcome domain for the evaluation of the effectiveness of therapy and the course of the disease. In an effort…
Abstract Number: 416 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 (DAS28)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient self- monitoring of disease activity may enhance treatment by providing early…
Abstract Number: 383 • 2014 ACR/ARHP Annual Meeting
How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry
Edward C. Keystone¹, Boulos Haraoui², John Kelsall³, Carter Thorne⁴, Philip Baer⁵, William Bensen⁶, Denis Choquette⁷, Regan Arendse⁸, Dalton Sholter⁹, Niall Jones¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, May Shawi¹³, Allen J Lehman¹⁴ and Susan Otawa¹⁴, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²University of Montreal Hospital Centre, Montreal, QC, Canada, ³The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹¹194 Main Street, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Composite measures of disease activity can facilitate clinical decision-making to achieve treatment goals, and treating-to-target has been shown to improve outcomes. Both CRA and…
Abstract Number: 384 • 2014 ACR/ARHP Annual Meeting
Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)
Erin Carruthers¹, Noura AL Osaimi², Charles H Goldsmith³, Paul Adam⁴ and Diane Lacaille⁵, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁵Arthritis Research Centre of Canada, Vancouver, BC, Canada
Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient involvement in monitoring their disease activity could enhance treatment by providing…
Abstract Number: 58 • 2014 ACR/ARHP Annual Meeting
What Does the Patient Global Assessment Mean for Patients with Psoriatic Arthritis? A Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis
Sandra Tälli¹, Adrien Etcheto², Bruno Fautrel³, Andra Balanescu⁴, Jürgen Braun⁴, Juan D. Cañete⁵, Kurt de Vlam⁴, Maarten de Wit⁴, Turid Heiberg⁴, Philip S. Helliwell⁴, Umut Kalyoncu⁴, Uta Kiltz⁶, Mara Maccarone⁴, Dora Niedermayer⁴, Kati Otsa⁴, Rossana Scrivo⁴, Josef Smolen⁴, Tanja Alexandra Stamm⁴, Douglas J. Veale⁷, Tore K. Kvien⁴ and Laure Gossec³, ¹Rheumatology, GRC UPMC Paris 06 University, Pitie-Salpétriere hospital, Paris, France, ²Cochin Hospital, Paris Descartes University, Paris, France, ³Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁴PsAID taskforce, EULAR, Zurich, Switzerland, ⁵Rheumatology, Hospital Clinic, Barcelona, Spain, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Translational Rheumatology Research Group, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose Patient global assessment (PGA) is one of the most widely used patient reported outcomes (PROs) in psoriatic arthritis (PsA). PGA should reflect the global…
Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman² and Vinod Chandran², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
Abstract Number: 2828 • 2014 ACR/ARHP Annual Meeting
A Physically Demanding Job May Amplify the Effect of Disease Activity on the Development of Syndesmophytes in Patients with Ankylosing Spondylitis
Sofia Ramiro^1,2, A.M. van Tubergen³, Robert Landewé^4,5, Annelies Boonen⁶, Carmen Stolwijk⁷, Maxime Dougados⁸, Filip van Den Bosch⁹ and Desiree van der Heijde¹⁰, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ³Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Atrium Medical Center, Heerlen, Netherlands, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁷Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁸Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁹Ghent University Hospital, Ghent, Belgium, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have recently shown that disease activity is longitudinally associated with radiographic progression in AS. In animal models, it has recently been shown that…
Abstract Number: 2768 • 2014 ACR/ARHP Annual Meeting
Patient Reported Outcomes and Acute Phase Reactants in Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone
Mauro Betelli, Giulia Erba, Massimo Ricci, Carlo Valena, Elisabetta Allevi, Marta Riva, Giorgia Grosso, Simona Barbarossa, Federica Bonomi and Maria Rosa Pozzi, Department of Internal Medicine, Rheumatology Outpatient Clinic - San Gerardo Hospital – Milano-Bicocca University, Monza, Italy
Background/Purpose Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder of the elderly, characterised by morning stiffness, pain and aching in the hip and shoulder girdles…
Abstract Number: 2707 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Related Calcinosis: Patients Provide What Specialists Want to Learn
Angela Christensen¹, Samara Khalique², Sophia Cenac³, Kim Fligelstone⁴, Anne Mawdsley⁵, Tracy Frech⁶, Jessica K. Gordon⁷, Murray Baron⁸, Evan Busman⁹, Virginia D. Steen¹⁰ and Lesley Ann Saketkoo¹¹, ¹Tulane University School of Medicine, New Orleans, LA, ²Louisiana State University Health Sciences Center, New Orleans, LA, ³Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, ⁶Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, ⁹Atlanta Scleroderma Support Group, Atlanta, GA, ¹⁰Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Calcinosis is a disabling, rarely discussed manifestation of SSc for which the natural history and management is poorly understood. Last year, the Scleroderma Clinical…
Abstract Number: 2632 • 2014 ACR/ARHP Annual Meeting
The Cornerstone to Reasonable Allocation of Health Resource: Valuation of Health Utility in Systemic Lupus Erythematosus
Suli Wang and Liangjing Lu, Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: In a time of increasing economic constraints, it is crucial that health systems optimize their resource use to ensure that they generate the maximum…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].